A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs AZD-1775 (Primary) ; Durvalumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 Jul 2017 Planned End Date changed from 30 Mar 2018 to 31 May 2018.
- 06 Jul 2017 Planned primary completion date changed from 30 Mar 2018 to 31 May 2018.
- 01 May 2017 Planned number of patients changed from 42 to 55.